Marcelo Orias, MD, PhD
Associate ProfessorCards
Appointments
Additional Titles
Affiliated Faculty, Yale Institute for Global Health
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAppointments
Additional Titles
Affiliated Faculty, Yale Institute for Global Health
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAppointments
Additional Titles
Affiliated Faculty, Yale Institute for Global Health
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAbout
Titles
Associate Professor
Affiliated Faculty, Yale Institute for Global Health
Appointments
Nephrology
Associate Professor on TermPrimary
Other Departments & Organizations
- Global Health Studies
- Internal Medicine
- Nephrology
- Polycystic Kidney Disease Program
- Yale Institute for Global Health
- Yale Medicine
Education & Training
- PhD
- University of Cordoba (2003)
- MD
- National University of Cordoba (1987)
Research
Research at a Glance
Yale Co-Authors
Publications Timeline
Gary Désir, MD
Aldo Peixoto, MD
Susan T Crowley, MD, MBA, FASN
Margaret Bia, MD
Mark Perazella, MD
Richard Formica, MD
Publications
2023
It is strongly recommended to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals’ sodium (salt) intake in association with health outcomes: a policy statement of the World Hypertension League, International Society of Hypertension and Resolve to Save Lives
Campbell N, Whelton P, Orias M, Cobb L, Jones E, Garg R, Willliams B, Khan N, Chia Y, Jafar T, Ide N. It is strongly recommended to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals’ sodium (salt) intake in association with health outcomes: a policy statement of the World Hypertension League, International Society of Hypertension and Resolve to Save Lives. Journal Of Hypertension 2023, 41: 683-686. PMID: 36723484, PMCID: PMC10090307, DOI: 10.1097/hjh.0000000000003385.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsSpot urine samplesSodium intakeIndividual sodium intakeWorld Hypertension LeagueHealth outcomesUrine samplesHealth outcome associationsOutcome associationsInternational SocietyDietary sodiumHealth OrganizationIntakeHypertensionHealth impactsShort durationOutcomesAssociationSubstantial controversyLiterature reviewPolicy statements
2022
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients
Coyne DW, Singh AK, Lopes RD, Bailey CK, DiMino TL, Huang C, Connaire J, Rastogi A, Kim SG, Orias M, Shah S, Patel V, Cobitz AR, Wanner C. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1325-1336. PMID: 35918106, PMCID: PMC9625096, DOI: 10.2215/cjn.00550122.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsErythropoiesis-stimulating agentsTimes weekly dosingTRIAL REGISTRY NAMESecondary end pointsTreatment of anemiaEpoetin groupDaprodustat groupEnd pointWeekly dosingREGISTRY NAMEHemoglobin valuesMean changeHypoxia-inducible factor prolyl hydroxylase inhibitorCLINICAL TRIAL REGISTRY NAMEPrincipal secondary end pointTreatment-emergent adverse eventsIntravenous iron doseIntravenous iron usePrimary end pointChronic kidney diseaseMean hemoglobin valuesEvaluation periodProlyl hydroxylase inhibitorBaseline hemoglobinPrevalent hemodialysisBedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension
Stergiou G, Brunström M, MacDonald T, Kyriakoulis KG, Bursztyn M, Khan N, Bakris G, Kollias A, Menti A, Muntner P, Orias M, Poulter N, Shimbo D, Williams B, Adeoye AM, Damasceno A, Korostovtseva L, Li Y, Muxfeldt E, Zhang Y, Mancia G, Kreutz R, Tomaszewski M. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. Journal Of Hypertension 2022, 40: 1847-1858. PMID: 35983870, DOI: 10.1097/hjh.0000000000003240.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAntihypertensive drugsAntihypertensive medicationsBedtime dosingOutcome trialsDrug dosingClinical practiceEfficient medical interventionsHypertension position paperMorning BP surgeNight-time hypertensionAntihypertensive drug therapyAntihypertensive drug treatmentSingle morning doseBlood pressure profileEffective treatment strategiesWorld Hypertension LeagueInternational SocietyAntihypertensive treatmentBedtime administrationBP controlBP surgeMorning doseMorning dosingCardiovascular eventsAdverse prognosis2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action
Campbell NRC, Whelton PK, Orias M, Wainford RD, Cappuccio FP, Ide N, Neal B, Cohn J, Cobb LK, Webster J, Trieu K, He FJ, McLean RM, Blanco-Metzler A, Woodward M, Khan N, Kokubo Y, Nederveen L, Arcand J, MacGregor GA, Owolabi MO, Lisheng L, Parati G, Lackland DT, Charchar FJ, Williams B, Tomaszewski M, Romero CA, Champagne B, L’Abbe M, Weber MA, Schlaich MP, Fogo A, Feigin VL, Akinyemi R, Inserra F, Menon B, Simas M, Neves MF, Hristova K, Pullen C, Pandeya S, Ge J, Jalil JE, Wang JG, Wideimsky J, Kreutz R, Wenzel U, Stowasser M, Arango M, Protogerou A, Gkaliagkousi E, Fuchs FD, Patil M, Chan AW, Nemcsik J, Tsuyuki RT, Narasingan SN, Sarrafzadegan N, Ramos ME, Yeo N, Rakugi H, Ramirez AJ, Álvarez G, Berbari A, Kim CI, Ihm SH, Chia YC, Unurjargal T, Park HK, Wahab K, McGuire H, Dashdorj NJ, Ishaq M, Ona DID, Mercado-Asis LB, Prejbisz A, Leenaerts M, Simão C, Pinto F, Almustafa BA, Spaak J, Farsky S, Lovic D, Zhang XH. 2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action. Journal Of Human Hypertension 2022, 37: 428-437. PMID: 35581323, PMCID: PMC9110933, DOI: 10.1038/s41371-022-00690-0.Peer-Reviewed Original ResearchCitationsAltmetricImplementación de la Iniciativa HEARTS en Argentina: primeros resultados
Rodriguez G, Rosende A, Prado C, Mariño R, Irazola V, DiPette D, Orias M, Arcila G, Laspiur S. Implementación de la Iniciativa HEARTS en Argentina: primeros resultados. BULL PAN AM HEALTH ORGAN 2022, 46: e181. PMID: 36160765, PMCID: PMC9491484, DOI: 10.26633/rpsp.2022.181.Peer-Reviewed Original ResearchCitationsConceptsCombination therapyHearts InitiativePrimary health care centersStandardized treatment protocolMain risk factorsHealth care centersCause of mortalityBlood pressure measurement devicesArterial hypertensionRisk factorsCare centerTherapy levelsCardiovascular diseaseHealth centersTreatment protocolHealth teamsBaseline valuesParadoxical decreasePressure measurement deviceClinical competencyPeriod of restrictionHypertensionGeneralized reductionCOVID-19Therapy
2021
Is Isolated Diastolic Hypertension an Important Phenotype?
Romero CA, Tabares AH, Orias M. Is Isolated Diastolic Hypertension an Important Phenotype? Current Cardiology Reports 2021, 23: 177. PMID: 34657205, PMCID: PMC8753786, DOI: 10.1007/s11886-021-01609-w.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNarrow pulse pressureDiastolic hypertensionCardiovascular riskPulse pressureLong-term cardiovascular riskRecent FindingsRecent guidelinesHypertension subgroupIDH definitionsIDH prevalenceHypertensive patientsYounger patientsRisk stratificationEpidemiological characteristicsTherapeutic decisionsPharmacological interventionsHypertension phenotypesCutoff levelHypertensionImportant subgroupPatientsPathophysiologyRiskSubgroupsIDHLong termASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three Times Weekly in Hemodialysis Patients
Coyne D, Singh A, Lopes R, Bailey C, Dimino T, Huang C, Connaire J, Rastogi A, Kim S, Orias M, Shah S, Patel V, Cobitz A, Wanner C. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three Times Weekly in Hemodialysis Patients. Journal Of The American Society Of Nephrology 2021, 32: 191-191. DOI: 10.1681/asn.20213210s1191b.Peer-Reviewed Original ResearchCitationsErratum to “Second Consensus on Treatment of Patients Recently Diagnosed with Mild Hypertension and Low Cardiovascular Risk”. [YMCD 45/10 (October 2020) 100653]
Morales-Salinas A, Olsen M, Kones R, Kario K, Wang J, Beilin L, Weber M, Yano Y, Burrell L, Orias M, Dzudie A, Lavie C, Ventura H, Sundström J, de Simone G, Coca A, Rumana U, Marrugat J. Erratum to “Second Consensus on Treatment of Patients Recently Diagnosed with Mild Hypertension and Low Cardiovascular Risk”. [YMCD 45/10 (October 2020) 100653]. Current Problems In Cardiology 2021, 46: 100877. PMID: 34148707, DOI: 10.1016/j.cpcardiol.2021.100877.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLlamado a la acción de San Pablo para la prevención y el control de la hipertensión arterial, 2020
Campbell NR, Schutte AE, Varghese CV, Ordunez P, Zhang XH, Khan T, Sharman JE, Whelton PK, Parati G, Weber MA, Orías M, Jaffe MG, Moran AE, Plavnik FL, Ram VS, Brainin M, Owolabi MO, Ramirez AJ, Barbosa E, Bortolotto LA, Lackland DT. Llamado a la acción de San Pablo para la prevención y el control de la hipertensión arterial, 2020. BULL PAN AM HEALTH ORGAN 2021, 45: 1. PMID: 33643404, PMCID: PMC7905751, DOI: 10.26633/rpsp.2021.26.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetric
2020
Standardized treatment to improve hypertension control in primary health care: The HEARTS in the Americas Initiative
DiPette DJ, Goughnour K, Zuniga E, Skeete J, Ridley E, Angell S, Brettler J, Campbell NRC, Coca A, Connell K, Doon R, Jaffe M, Lopez‐Jaramillo P, Moran A, Orias M, Pineiro DJ, Rosende A, González YV, Ordunez P. Standardized treatment to improve hypertension control in primary health care: The HEARTS in the Americas Initiative. Journal Of Clinical Hypertension 2020, 22: 2285-2295. PMID: 33045133, PMCID: PMC8029673, DOI: 10.1111/jch.14072.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsAntihypertensive medicationsCardiovascular diseaseTreatment protocolHypertension controlBurden of CVDCVD secondary preventionEffective antihypertensive medicationsMajor hypertension guidelinesRisk factor mitigationControl of hypertensionFixed-dose combinationPrimary health carePost-program implementationCommunity-based programsHypertension guidelinesSecondary preventionBlood pressureCVD burdenInitial treatmentPharmacologic protocolRisk factorsStandardized treatmentMedication formulariesSingle pillHypertension
Academic Achievements & Community Involvement
activity ISN North America and the Caribbean Regional Board
Professional OrganizationsMemberDetails08/22/2021 - Presentactivity Local Organizing Working Group for World Congress of Nephrology
Professional OrganizationsMemberDetails2022 - Presentactivity ISN World Congress of Nephrology 2024
Professional OrganizationsCo-ChairDetails04/13/2024 - 04/16/2024honor Teacher of the Year Award
Other AwardGreenwich HospitalDetails07/01/2021United Statesactivity ISN Latin American Regional Board
Professional OrganizationsMemberDetails2019 - 2021
Clinical Care
Overview
Marcelo Orias, MD, PhD, is a nephrologist and sees patients with general kidney disease, but also specializes in treating hypertension, which is common in patients with chronic kidney disease.
A fourth-generation physician, Dr. Orias says he always knew he wanted to be a doctor, but he didn’t settle on nephrology as a specialty until medical school. “It’s probably in my genes to be a doctor, and when I discovered nephrology I enjoyed its physiology,” he says. “It’s very complex.”
When meeting with patients, Dr. Orias says he tries to use common words to break down the complexity and to illustrate how the kidneys work and how certain diseases affect their function.
“The kidneys are probably the main reason why people have high blood pressure. It’s a vicious circle where increased blood pressure makes the kidneys worse, and it’s important that this is noticed and treated or else a patient can end up on dialysis,” Dr. Orias says. “But if we catch it early enough, it can be treated with dietary and lifestyle changes and blood pressure medication.”
Part of the problem, he explains, is that you can have problems in your kidneys and not know it. “As we age, our blood pressure increases. Roughly sixty percent of people who are 60 years old have hypertension and 90 percent of those who are 90 have it. It’s very important to have your blood work checked because you can have damage to your kidneys and be asymptomatic,” says Dr. Orias, who also treats many young patients, a population that is increasing in kidney disease.
His research interests include phenotypes in hypertension. Dr. Orias is also vice president of the World Hypertension League, an organization dedicated to addressing hypertension at the population level.
Clinical Specialties
Fact Sheets
Polycystic Kidney Disease (PKD)
Learn More on Yale Medicine
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor Profile